This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, M. Articles by Xu, X.-C. Search for Related Content PubMed PubMed Citation Articles by Li, M. Articles by Xu, X.-C.

Aspirin Induction of Apoptosis in Esophageal Cancer: A Potential for Chemoprevention¹

Departments of Clinical Cancer Prevention [M. L., S. M. L., X-C. X.] and Thoracic/Head & Neck Medical Oncology [R. L.] and Division of Cancer Prevention [R. L., B. L.], University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and the First Department of Pathology, Hiroshima University, School of Medicine, Hiroshima, Japan [E. T.]

The potential use of non-steroidal anti-inflammatory drugs (NSAIDs) in the prevention of gastrointestinal cancers has been highlighted recently. However, it is not known whether NSAIDs could also be useful for preventing esophageal cancer, although regular users of these drugs appear to have a decreased incidence of esophageal cancer. Therefore, we examined the effect of aspirin on growth and apoptosis in 10 esophageal cancer cell lines as well as the expression and modulation of its target enzymes, cyclooxygenases (COXs), and their product prostaglandin E₂. Growth inhibition of these cells by aspirin was dose- and time-dependent and associated with the induction of apoptosis. COX-1 and COX-2 were expressed in 7 of the 10 cell lines. Bile acids could induce COX-2 expression in six of eight cell lines tested, which was correlated with prostaglandin E₂ production, and aspirin could inhibit COX-2 enzymatic activity even after bile acid stimulation but was unable to change the COX-2 protein level in these cell lines. Down-regulation of bcl-2 by aspirin was found in the two cell lines tested. These results suggest that induction of apoptosis by aspirin may be a mechanism by which it can intervene in esophageal carcinogenesis and may be indicative of the potential of NSAIDs as chemopreventive agents in esophageal cancer.

This article has been cited by other articles:

				L. A. Anderson, B. T. Johnston, R.G. P. Watson, S. J. Murphy, H. R. Ferguson, H. Comber, J. McGuigan, J. V. Reynolds, and L. J. Murray Nonsteroidal Anti-inflammatory Drugs and the Esophageal Inflammation-Metaplasia-Adenocarcinoma Sequence. Cancer Res., May 1, 2006; 66(9): 4975 - 4982. [Abstract] [Full Text] [PDF]

				H. H.-X. Xia, S. T. Zhang, S. K. Lam, M. C.-M. Lin, H. F. Kung, and B. C.-Y. Wong Expression of macrophage migration inhibitory factor in esophageal squamous cell carcinoma and effects of bile acids and NSAIDs Carcinogenesis, January 1, 2005; 26(1): 11 - 15. [Abstract] [Full Text] [PDF]

				G. D. Basu, L. B. Pathangey, T. L. Tinder, M. LaGioia, S. J. Gendler, and P. Mukherjee Cyclooxygenase-2 Inhibitor Induces Apoptosis in Breast Cancer Cells in an In vivo Model of Spontaneous Metastatic Breast Cancer Mol. Cancer Res., November 1, 2004; 2(11): 632 - 642. [Abstract] [Full Text] [PDF]

				O. N. Tucker, A. J. Dannenberg, E. K. Yang, and T. J. Fahey III Bile acids induce cyclooxygenase-2 expression in human pancreatic cancer cell lines Carcinogenesis, March 1, 2004; 25(3): 419 - 423. [Abstract] [Full Text] [PDF]

				J. E. Castelao, R. D. Bart III, C. A. DiPerna, E. M. Sievers, and R. M. Bremner Lung cancer and cyclooxygenase-2 Ann. Thorac. Surg., October 1, 2003; 76(4): 1327 - 1335. [Abstract] [Full Text] [PDF]

				X. Chen, N. Li, S. Wang, J. Hong, M. Fang, J. Yousselfson, P. Yang, R. A. Newman, R. A. Lubet, and C. S. Yang Aberrant arachidonic acid metabolism in esophageal adenocarcinogenesis, and the effects of sulindac, nordihydroguaiaretic acid, and {alpha}-difluoromethylornithine on tumorigenesis in a rat surgical model Carcinogenesis, December 1, 2002; 23(12): 2095 - 2102. [Abstract] [Full Text] [PDF]

				T. L. Vaughan, A. R. Kristal, P. L. Blount, D. S. Levine, P. C. Galipeau, L. J. Prevo, C. A. Sanchez, P. S. Rabinovitch, and B. J. Reid Nonsteroidal Anti-inflammatory Drug Use, Body Mass Index, and Anthropometry in Relation to Genetic and Flow Cytometric Abnormalities in Barrett's Esophagus Cancer Epidemiol. Biomarkers Prev., August 1, 2002; 11(8): 745 - 752. [Abstract] [Full Text] [PDF]

				P. S. Carlton, R. Gopalakrishnan, A. Gupta, B. W. Liston, S. Habib, M. A. Morse, and G. D. Stoner Piroxicam Is an Ineffective Inhibitor of N-Nitrosomethylbenzylamine-induced Tumorigenesis in the Rat Esophagus Cancer Res., August 1, 2002; 62(15): 4376 - 4382. [Abstract] [Full Text] [PDF]

				M. J. Thun, S. J. Henley, and C. Patrono Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266. [Abstract] [Full Text] [PDF]

				I. Shureiqi, X. Xu, D. Chen, R. Lotan, J. S. Morris, S. M. Fischer, and S. M. Lippman Nonsteroidal Anti-Inflammatory Drugs Induce Apoptosis in Esophageal Cancer Cells by Restoring 15-Lipoxygenase-1 Expression Cancer Res., June 1, 2001; 61(12): 4879 - 4884. [Abstract] [Full Text] [PDF]

				M. Li, X. Wu, and X.-C. Xu Induction of Apoptosis in Colon Cancer Cells by Cyclooxygenase-2 Inhibitor NS398 through a Cytochrome c-dependent Pathway Clin. Cancer Res., April 1, 2001; 7(4): 1010 - 1016. [Abstract] [Full Text]

				W. K. Hong, M. R. Spitz, and S. M. Lippman Cancer Chemoprevention in the 21st Century: Genetics, Risk Modeling, and Molecular Targets J. Clin. Oncol., November 1, 2000; 18(90001): 9s - 18. [Full Text] [PDF]